Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration

Abstract. Introduction:. A subgroup analysis of the CAPACITY and ASCEND trials showed that pirfenidone use beyond disease progression reduced the risk of subsequent forced vital capacity (FVC) decline and death. Our study aimed to compare the efficacy and safety of nintedanib with or without pirfeni...

Full description

Bibliographic Details
Main Authors: Satoshi Ikeda, MD, PhD, Akimasa Sekine, MD, PhD, Tomohisa Baba, MD, Terufumi Kato, MD, Takuma Katano, MD, Erina Tabata, MD, Ryota Shintani, MD, Hideaki Yamakawa, MD, PhD, Tsuneyuki Oda, MD, PhD, Ryo Okuda, MD, Hideya Kitamura, MD, PhD, Tae Iwasawa, MD, PhD, Tamiko Takemura, MD, PhD, Takashi Ogura, MD, Jorddy Neves Cruz.
Format: Article
Language:English
Published: Wolters Kluwer 2022-06-01
Series:Medicine
Online Access:http://journals.lww.com/10.1097/MD.0000000000029232

Internet

http://journals.lww.com/10.1097/MD.0000000000029232

Similar Items